{"id":"pvrv-and-perig-favirab","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1628401","moleculeType":"Small molecule","molecularWeight":"657.81"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Favirab® is a monoclonal antibody-based rabies immunoglobulin designed to neutralize rabies virus particles and prevent viral entry into cells. It is administered as part of post-exposure prophylaxis (PEP) regimens following potential rabies exposure, working synergistically with rabies vaccine to provide rapid passive immunity while the vaccine generates active immunity. PVRV and pERIG refer to different formulations or manufacturing processes for this rabies immunoglobulin product.","oneSentence":"PVRV and pERIG Favirab® are rabies immunoglobulins that provide passive post-exposure prophylaxis by neutralizing rabies virus through direct antibody binding.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:30:46.712Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Post-exposure prophylaxis of rabies following potential rabies virus exposure"}]},"trialDetails":[{"nctId":"NCT01622062","phase":"PHASE3","title":"Immunogenicity and Safety of Verorab® in a \"One-week\" Intradermal Post-exposure Prophylaxis Regimen","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-06-29","conditions":"Rabies","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["VERORAB®; pERIG Favirab®"],"phase":"phase_3","status":"active","brandName":"PVRV and pERIG Favirab®","genericName":"PVRV and pERIG Favirab®","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"PVRV and pERIG Favirab® are rabies immunoglobulins that provide passive post-exposure prophylaxis by neutralizing rabies virus through direct antibody binding. Used for Post-exposure prophylaxis of rabies following potential rabies virus exposure.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}